Denmark-listed drugs developer H Lundbeck has invested £10.3m ($16m) in UK-based Proximagen Group as part of a strategic partnership to treat central nervous system (CNS) disorders. Lundbeck is buying 5.7 million shares at £1.80 each, a 36% premium over its six-month average price before the offer. A steering committee from both companies will focus on…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
